Recce Pharmaceuticals (ASX:RCE) secured clearance from an independent non-data safety review board to continue a phase 2 clinical trial evaluating the Recce 327 topical gel as a potential antibacterial product for acute skin infections, including diabetic foot infections, according to a Monday filing with the Australian bourse.

The disclosure follows a safety and efficacy review in which no serious adverse events were noted, the filing said.

Company shares fell almost 5% at market close on Monday.

Price (AUD): $0.48, Change: $-0.025, Percent Change: -4.95%